Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford University scientist have discovered the molecular ‘first responder’ which detects disturbances in the flow of blood through the arteries, and responds by encouraging the formation of plaques which can lead to serious problems, including heart attack, stroke and even death.

Atherosclerosis, Cholesterol plaque in artery. 3d illustration

The study, published in the journal Nature, found that mice without this molecule in its right shape don’t have clogged arteries, even when they eat an unhealthy high fat diet.

Atherosclerosis is a potentially fatal disease where fatty plaques clog up the arteries supplying blood to the heart, brain and other organs. These plaques cause the arteries to narrow and can increase the risk of blood clots that could block blood flow to the heart or brain, making it more likely that patients with atherosclerosis will suffer from heart attacks or strokes.

But scientists have known for over 200 years that the plaques don’t form just anywhere in the arteries – they are much more likely to form where the arteries curve or split, causing whorls and eddies in the blood flowing through them.

Read the full story on the University of Oxford website

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.